As the number of mechanisms and thus possible targets is steadily increasing, a key question arises – can modulation of one metabolic pathway, such as through IDO1 blockade, influence the outcome of immune-cancer interaction to induce tumor regression? The gene discussed is IDO1; the disease is cancer.